Annexon, Inc.NASDAQ: ANNX

Annexon to Participate in Upcoming September Investor Conferences

· Issued by Annexon, Inc. via GlobeNewswire

Summary by 6ix AI

Annexon, Inc., a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases, said its president and chief executive officer Douglas Love will take part in fireside chats at three investor conferences in September 2026.

Key details

  • Wells Fargo 21st Annual Healthcare Conference: Wednesday, September 9, 2026, at 8:45 a.m. ET in Boston, MA.
  • Cantor Global Healthcare Conference: Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY.
  • H.C. Wainwright 28th Annual Global Investment Conference: Tuesday, September 15, 2026, at 1:00 p.m. ET in New York, NY.
  • Live webcasts will be available in the Events & Presentations section of the Investors page at annexonbio.com, with replays archived on the Annexon website for 30 days after the presentations.

6ix AI wrote this summary from the release below and checked it against the release.

BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:

  • Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 8:45 a.m. ET in Boston, MA; and,

  • Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 1:35 p.m. ET in New York, NY; and,

  • H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 1:00 p.m. ET in New York, NY.

Live webcasts of the presentations can be accessed under the 'Events & Presentations' section on the Investors page at annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon's mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
[email protected]

Media Contact:
Beth Keshishian
917-912-7195
[email protected]

Annexon, Inc. on 6ix

Story so far

Earlier from Annexon

Later from Annexon

All Annexon news releases